Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 18/20 | 1.00 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.72 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.42 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29410964 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3MAP4K4PRKCDMINK1 | |
| SCHEMBL26004417 | 0.97 | S1PR1 (0.95) | S1PR1S1PR3MAP4K4PRKCDMINK1 | |
| SCHEMBL15662160 | 0.95 | S1PR1 (0.91) | S1PR1S1PR3MAP4K4PRKCDMINK1 | |
| SCHEMBL15662886 | 0.94 | S1PR1 (0.88) | S1PR1S1PR3MAP4K4PRKCDMINK1 | |
| SCHEMBL9996208 | 0.93 | S1PR1 (0.86) | S1PR1S1PR3 | |
| SCHEMBL25596377 | 0.90 | S1PR1 (0.82) | S1PR1S1PR3MAP4K4PRKCDMINK1 | |
| SCHEMBL15662515 | 0.90 | S1PR1 (0.82) | S1PR1S1PR3MAP4K4PRKCDMINK1 | |
| SCHEMBL15661823 | 0.90 | S1PR1 (0.82) | S1PR1S1PR3MAP4K4PRKCDMINK1 | |
| SCHEMBL17797426 | 0.90 | S1PR1 (0.82) | S1PR1S1PR3BCHEACHE | |
| SCHEMBL177434 | 0.90 | S1PR1 (0.82) | S1PR1S1PR3BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9707205-B2 | S1P receptors modulators and their use thereof | AKAAL PHARMA PTY LTD. (AU) | 2017-07-18 | — | — | US | claimed |
| EP-2344484-B1 | S1P RECEPTORS MODULATORS AND USE THEREOF | AKAAL PHARMA PTY LTD (AU) | 2016-06-08 | — | — | EP | claimed |
| US-20160038455-A1 | S1P RECEPTORS MODULATORS AND THEIR USE THEREOF | AKAAL PHARMA PTY LTD. (AU) | 2016-02-11 | — | — | US | claimed |
| US-9193716-B2 | S1P receptors modulators and their use thereof | AKAAL PHARMA PTY LTD. (AU) | 2015-11-24 | — | — | US | claimed |
| US-8927553-B2 | Deuterium-enriched alkyl sulfonamides and uses thereof | DHANOA DALJIT SINGH (US) | 2015-01-06 | — | — | US | claimed |
| US-20140221395-A1 | Deuterium-Enriched Alkyl Sulfonamides and Uses Thereof | DHANOA DALJIT SINGH (US) | 2014-08-07 | — | — | US | claimed |
| WO-2014063199-A1 | ORGANIC COMPOUNDS | AKAAL PHARMA PTY LTD (AU) | 2014-05-01 | — | — | WO | claimed |
| US-20140066427-A1 | S1P Receptors Modulators and Their Use Thereof | AKAAL PHARMA PTY LTD. (AU) | 2014-03-06 | — | — | US | claimed |
| US-8592399-B2 | S1P receptors modulators and their use thereof | AKAAL PHARMA PTY LTD. (AU) | 2013-11-26 | — | — | US | claimed |
| US-20110318388-A1 | S1P Receptors Modulators and Their Use Thereof | AKAAL PHARMA PTY LTD (AU) | 2011-12-29 | — | — | US | claimed |
| US-20220135666-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR | GLAS USA LLC | 2022-05-05 | — | — | US | disclosed |
| US-9707205-B2 | S1P receptors modulators and their use thereof | AKAAL PHARMA PTY LTD. (AU) | 2017-07-18 | — | — | US | disclosed |
| US-9707205-B2 | S1P receptors modulators and their use thereof | AKAAL PHARMA PTY LTD. (AU) | 2017-07-18 | — | — | US | disclosed |
| WO-2017024355-A1 | COMPOSITIONS COMPRISING S1P RECEPTOR MODULATORS | AKAAL PHARMA PTY LTD (AU) | 2017-02-16 | — | — | WO | disclosed |
| US-9453027-B2 | Deuterium-enriched pyridinonecarboxamides and derivatives | DHANOA DALJIT SINGH (US) | 2016-09-27 | — | — | US | disclosed |
| US-20110318388-A1 | S1P Receptors Modulators and Their Use Thereof | AKAAL PHARMA PTY LTD (AU) | 2011-12-29 | — | — | US | disclosed |
| US-20110318388-A1 | S1P Receptors Modulators and Their Use Thereof | AKAAL PHARMA PTY LTD (AU) | 2011-12-29 | — | — | US | disclosed |
| EP-2344484-A1 | S1P RECEPTORS MODULATORS AND THEIR USE THEREOF | Akaal Pharma Pty Ltd (AU) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010043000-A1 | S1P RECEPTORS MODULATORS AND THEIR USE THEREOF | AKAAL PHARMA PTY LTD (AU) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010043000-A1 | S1P RECEPTORS MODULATORS AND THEIR USE THEREOF | AKAAL PHARMA PTY LTD (AU) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160038455-A1 | S1P RECEPTORS MODULATORS AND THEIR USE THEREOF | S1PR1, S1PR5, S1PR2 | S1PR1 1/4885S1PR3 4/4885MAP4K4 2544/4885 |
| US-20220135666-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR | S1PR2, S1PR1, S1PR4 | S1PR1 2/4885S1PR3 5/4885MAP4K4 2827/4885 |
| US-20110318388-A1 | S1P Receptors Modulators and Their Use Thereof | S1PR1, S1PR5, S1PR2 | S1PR1 1/4885S1PR3 4/4885MAP4K4 2544/4885 |
| US-20140066427-A1 | S1P Receptors Modulators and Their Use Thereof | S1PR1, S1PR2, S1PR5 | S1PR1 1/4885S1PR3 4/4885MAP4K4 2866/4885 |
| US-20140221395-A1 | Deuterium-Enriched Alkyl Sulfonamides and Uses Thereof | OPRD1, DBH, SNCA | S1PR1 3121/4885S1PR3 3061/4885MAP4K4 2836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.